title: The relationship between dosing of alosetron and discontinuation patterns reported by patients participating in a follow-up programme.
abstract: BACKGROUND
  Alosetron was reintroduced for treatment of irritable bowel syndrome with a risk management programme in November 2002. Recommended starting dosage was 1 mg/day for 4 weeks. If symptoms remained uncontrolled, dosage could be changed to 2 mg/day.
  
  
  OBJECTIVE
  To describe alosetron dosages and associated patient characteristics from the Lotronex follow-up survey programme.
  
  
  METHODS
  Patients reported dosages of alosetron at start and regular follow-up intervals. Analyses were limited to patients with the potential to have at least 1 year of follow-up (enrolled between 9 December 2002 and 31 December 2003).
  
  
  RESULTS
  At baseline, 75% of 2817 respondents reported starting on 1 mg/day, 17% on 2 mg/day and 8% on other doses. Adherence to recommended starting dosage did not vary by status at end of follow-up, previous alosetron experience or age. At last reported dose, 50% of respondents were using 1 mg/day; 29% were using 2 mg/day. Discontinuation was not related to baseline doses. Longer times to discontinuation were associated with previous use, symptoms for more than 6 months and dose change throughout follow-up.
  
  
  CONCLUSIONS
  High adherence to recommended dosing at baseline and follow-up suggests that the risk management programme is encouraging safe use of alosetron, including adherence to dosing recommendations.
authors.affiliation: RTI Health Solutions, Research Triangle Park, NC 27709-2194, USA. ptennis@rti.org
authors.forename: P
authors.initials: P
authors.lastname: Tennis
authors.forename: E
authors.initials: E
authors.lastname: Andrews
authors.forename: P
authors.initials: P
authors.lastname: Hickman
authors.forename: D
authors.initials: D
authors.lastname: Miller
authors.forename: K
authors.initials: K
authors.lastname: Hollis
authors.forename: S
authors.initials: S
authors.lastname: Cook
mesh_terms: D000328:Adult; D000368:Aged; D002243:Carbolines / Q000008:administration & dosage*; D005260:Female; D005500:Follow-Up Studies; D005765:Gastrointestinal Agents / Q000008:administration & dosage*; D006801:Humans; D043183:Irritable Bowel Syndrome / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010349:Patient Compliance / Q000523:psychology
chemical_list: D002243:Carbolines; D005765:Gastrointestinal Agents; C090840:alosetron